Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
June 18, 2025
Lock brings over 20 years of commercial leadership experience as Sling prepares for confirmatory Phase 3 study of linsitinib Sling Therapeutics, Inc., a biopharmaceutical company